Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Yanai S.,,Nivolumab-Induced Colitis Treated by Infliximab,2017,Clinical Gastroenterology and Hepatology,33,10.1016/j.cgh.2016.09.017,Japan,Article,Morioka,1,Journal,2-s2.0-85008205589
Postow M.,,Managing immune checkpoint-blocking antibody side effects,2015,American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting,232,10.14694/EdBook_AM.2015.35.76,United States,Review,New York,0,Journal,2-s2.0-84969710115
Van Den Brande J.,,Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease,2007,Gut,132,10.1136/gut.2006.105379,Netherlands,Article,Amsterdam,1,Journal,2-s2.0-34147211616
Van den Brande J.M.H.,,Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease,2003,Gastroenterology,641,10.1016/S0016-5085(03)00382-2,Netherlands,Article,Amsterdam,0,Journal,2-s2.0-0038047689
Sandborn W.,,"Etanercept for active Crohnâ€™s disease: A randomized, double-blind, placebo-controlled trial",2001,Gastroenterology,763,10.1053/gast.2001.28674,United States,Article,Rochester,0,Journal,2-s2.0-0034754477
